Sales success comes with side effects for drug maker BeiGene
The Chinese biotech’s product revenues surged nearly 82% in the second quarter, driven by forecast-beating sales of its core cancer drugs Key Takeaways: Global sales of BeiGene's anti-tumor drug zanubrutinib…
FAST NEWS: Antengene Acquires Full Interest in Anti-Tumor Cancer Drug
The latest: Biopharmaceutical company Antengene Corp. Ltd. (6996.HK) said on Wednesday it has agreed to acquire the remaining interest it doesn’t already hold in the anti-tumor drug ATG-037 from Calithera Biosciences (CALA.US), giving…
